AstraZeneca CFO Sarin on Earnings, Covid, M&A Pipeline

The transcript discusses AstraZeneca's strong quarterly performance, highlighting growth in oncology and cardiovascular sectors, and the acquisition of Alexion. The company emphasizes innovation, spending significantly on R&D, and achieving notable success with a new oncology drug. COVID-19 treatments and vaccines have saved millions of lives, with a focus on immunocompromised patients. The strong dollar impacts earnings, while China's market faces challenges due to pricing policies. AstraZeneca maintains a robust pipeline and focuses on cost management and supply chain resilience.

What were the earnings per share reported by AstraZeneca?

What therapeutic areas showed growth for AstraZeneca?

What challenges is AstraZeneca facing regarding oncology products?

How much did AstraZeneca spend on R&D in the last quarter?

What is the impact of the strong dollar on AstraZeneca's earnings?

What is AstraZeneca's strategy regarding acquisitions?

How has AstraZeneca's supply chain been affected in recent years?